Progress advance in the application of immune checkpoint inhibitors in the treatment of non-small cell lung cancer

Lianmin Zhang, D. Yue, Zhenfa Zhang
{"title":"Progress advance in the application of immune checkpoint inhibitors in the treatment of non-small cell lung cancer","authors":"Lianmin Zhang, D. Yue, Zhenfa Zhang","doi":"10.3760/CMA.J.ISSN.1673-4181.2019.03.010","DOIUrl":null,"url":null,"abstract":"Lung cancer is the most common malignant tumor in the world. In order to improve the survival rate of patients with advanced lung cancer, more effective treatment methods are needed, in which immunotherapy has a broad therapeutic prospect. In recent years, immune-checkpoint inhibitors have received extensive attention in the treatment of lung cancer. Significant progress has been made in the development of a variety of first-line and second-line treatments, and significant advances have been made in the treatment of advanced lung cancer. With the successful application of immune-checkpoint inhibitors, neoadjuvant therapy has attracted extensive attention. In addition, the successful application of combined therapies such as immune combined immunization, immune combined tyrosine kinase inhibitor (TKI) and immune combined chemotherapy improved the survival rate of patients to some extent. However, pseudo progression and drug resistance has become a non-negligible problem in the immunotherapy of non-small cell lung cancer, which is worthy of further study. Although immune-checkpoint inhibitors have once again brought attention to tumor immunotherapy, their side effects are also worthy of attention. The recent advances in the application of immune-checkpoint inhibitors in lung cancer were summarized in order to provide a theoretical basis for its clinical application. \n \n \nKey words: \nNon-small cell lung cancer; Immunotherapy; Immune-checkpoint inhibitors; Neoadjuvant therapy; Pseudo progress","PeriodicalId":61751,"journal":{"name":"国际生物医学工程杂志","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际生物医学工程杂志","FirstCategoryId":"1087","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-4181.2019.03.010","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Lung cancer is the most common malignant tumor in the world. In order to improve the survival rate of patients with advanced lung cancer, more effective treatment methods are needed, in which immunotherapy has a broad therapeutic prospect. In recent years, immune-checkpoint inhibitors have received extensive attention in the treatment of lung cancer. Significant progress has been made in the development of a variety of first-line and second-line treatments, and significant advances have been made in the treatment of advanced lung cancer. With the successful application of immune-checkpoint inhibitors, neoadjuvant therapy has attracted extensive attention. In addition, the successful application of combined therapies such as immune combined immunization, immune combined tyrosine kinase inhibitor (TKI) and immune combined chemotherapy improved the survival rate of patients to some extent. However, pseudo progression and drug resistance has become a non-negligible problem in the immunotherapy of non-small cell lung cancer, which is worthy of further study. Although immune-checkpoint inhibitors have once again brought attention to tumor immunotherapy, their side effects are also worthy of attention. The recent advances in the application of immune-checkpoint inhibitors in lung cancer were summarized in order to provide a theoretical basis for its clinical application. Key words: Non-small cell lung cancer; Immunotherapy; Immune-checkpoint inhibitors; Neoadjuvant therapy; Pseudo progress
免疫检查点抑制剂在癌症治疗中的应用进展
癌症是世界上最常见的恶性肿瘤。为了提高晚期癌症患者的生存率,需要更有效的治疗方法,其中免疫疗法具有广阔的治疗前景。近年来,免疫检查点抑制剂在癌症治疗中受到广泛关注。各种一线和二线治疗方法的开发取得了重大进展,晚期癌症的治疗也取得了重大进步。随着免疫检查点抑制剂的成功应用,新辅助治疗引起了广泛关注。此外,免疫联合免疫、免疫联合酪氨酸激酶抑制剂(TKI)和免疫联合化疗等联合疗法的成功应用在一定程度上提高了患者的生存率。然而,假性进展和耐药性已成为癌症免疫治疗中不可忽视的问题,值得进一步研究。尽管免疫检查点抑制剂再次引起了人们对肿瘤免疫治疗的关注,但其副作用也值得关注。综述了免疫检查点抑制剂在癌症中应用的最新进展,为其临床应用提供理论依据。关键词:非小细胞肺癌;免疫治疗;免疫检查点抑制剂;新辅助治疗;伪进度
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
1974
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信